Modalities & Formats
Novocol Pharma supports a wide range of sterile injectable modalities and formats, whether a program arrives with a fully defined device platform or is still evaluating the best pathway forward. Our strengths span cartridge and prefilled syringe systems, peptide formulations, chronic disease therapeutics, and combination-product platforms such as pens, autoinjectors, and dual-chamber cartridges. Regardless of where a program begins, we flex to meet our customers’ needs while providing guidance where it adds meaningful value.
Pairing Our Expertise with Your Program Needs
Our clients partner with us at every level of program maturity. Some bring well-established components and device platforms ready for immediate tech transfer. Others are refining modality or container choices and require targeted feasibility input before locking in a final approach.
We are here are to help you:
Support customer-defined formats with deep technical and device knowledge
Offer feasibility insights when assistance is requested
Evaluate manufacturability, stability, and component fit for chosen systems
Identify risks and conduct FMEA early so programs progress smoothly and predictably
This adaptability ensures that whether programs are highly defined or still evolving, Novocol Pharma aligns with our customers’ strategy and operational needs.
Product Formats Supported
Cartridges are a core area of strength for Novocol Pharma, supported by Septodont’s long-standing global leadership in sterile cartridge manufacturing. Many programs enter with defined cartridge specifications, while others seek help aligning the format to the product and device.
Capabilities include:
- Support for a wide range of cartridges from 1 mL to 3 mL cartridges
- Integration with fixed-dose or multi-dose pens,
- Flexibility to work with client-selected components or validated equivalents
- High-volume commercial manufacturing capacity
Whether a client uses a specific syringe format, stopper, or autoinjector system, Novocol Pharma adapts processing to the requirements of the selected platform.
RTU isolator-based PFS can support:
- Peptides, biologics, GLP-1 agonists, and chronic therapies
- Pre-filled syringes, including those intended for us in autoinjectors
- Programs requiring reduced human intervention and rapid setup
For early-stage or specialty programs requiring vials, the RTU isolator line supports feasibility across 2R to 20R.
Modalities We Support
Peptide injectables are one of Novocol Pharma’s strongest growth areas. Whether the peptide formulation is fixed or evolving, Novocol Pharma supports:
- Stability studies, including physical, microbiological, and analytical testing for assays and impurities
- Device and material compatibility evaluations
- Processing strategies that protect shear-sensitive or adsorptive products
Many small-molecule sterile injectables arrive with well-defined formats and device expectations. Novocol Pharma supports these directly with established manufacturing methods and strong regulatory familiarity.
Biologic feasibility is supported through RTU, PFS, and vial workflows, aligned to either known or maturing product requirements.
Capabilities Across Modalities and Formats
Novocol Pharma’s cross-functional model ensures continuity from initial review through full-scale manufacturing. Support includes:
Supporting Technologies and Facility Advantages
Novocol Pharma’s infrastructure enables flexible support for both fixed and evolving program needs:
Multi-line cartridge and PFS filling
capability
Integrated QC
Chemistry and Microbiology
> 500,000
media fill units executed with zero positives
250,000 ft2
24/7 sterile manufacturing campus